July 17th, 2012|
July 17, 2012
In the wake of research finding an increased risk of bladder cancer in patients who took the diabetes drug Actos, thousands of drug injury claims have been filed across the country. According to a press release from the U.S. Food and Drug Administration, patients who take the drug have a 40 percent greater chance of developing the disease than those who didn’t take it.
The drug’s manufacturer, Takeda Pharmaceuticals, was found to be aware of the increased risk, but withheld the knowledge from the public. Court ruling found this to be evidence of negligence, which allowed those who were injured to more easily file claims.
On June 14, a Texas woman filed a lawsuit in U.S. District Court claiming that she developed bladder cancer after taking the drug from 2000 to 2005. A year later, doctors discovered she had developed a tumor on her bladder. The lawsuit alleges that the drug caused a series of adverse events, including severe mental and physical pain, permanent injuries resulting in physical and emotional distress, economic loss due to medical expenses, and living expenses as a result of a new lifestyle. The lawsuit also claims loss of consortium on behalf of the Plaintiff’s husband.
The Actos Injury Lawyers with Ferrer, Poirot & Wansbrough would encourage anyone who has experienced a negative reaction while taking the diabetes drug Actos to contact a Drug Injury Lawyer to discuss your case.
November 22nd, 2011|
November 22, 2011
The Food and Drug Administration (FDA) recently issued a warning about the increased risk of bladder cancer in patients taking the diabetes medication, Actos. According to WebMD Health News, the decision was the result of data culminated from a five-year study by the drug’s manufacturer, Takeda Pharmaceuticals, which showed an increase in the risk of the cancer in patients who had taken the drug over long periods of time or in large doses.
The study examined 193,000 diabetes patients taking Actos for an average of two years. Results stated, “Compared to never being exposed to pioglitazone, a duration of pioglitazone therapy longer than 12 months was associated with a 40 percent increase in risk [for bladder cancer].”
Since the decision, Actos has been pulled from European markets in Germany and France, and the FDA has warned doctors to refrain from starting new patients on the drug if they have bladder cancer or have suffered from bladder cancer in the past.
The Actos Drug Injury Lawyers with Ferrer, Poirot & Wansbrough have handled numerous cases for victims of drug injuries. If you suffer from an Actos drug injury, contact us today to discuss your case.